Volume 16 No 10 (2018)
 Download PDF
Comparative Study between Leviteracetam, Phenytoin & Carbamazepine in Treating Post Traumatic Epilepsy
Dr. Rana Hani Mohammed Ali Al-Shaikh Hamed , Dr. Raad Ahmed Hussein, Sadoon A. Ibraheem , Dr. Muhammed Hameed Faeadh Al Jumaily
Abstract
Aim: Evaluation of the advantages of Levetiracetam over Phenytoin & Carbamazepine in treatment of late post traumatic epilepsy. Objectives: To compare between the effectiveness of antiepileptic drugs leviteracetam, phenytoin & carbamazepine in management of post-traumatic epilepsy. Methods: This is a retrospective study on the medical treatment of 60 patients with post traumatic epilepsy. 20 patients of them were treated by leviteracetam, 20 patients by Tegretol, & 20 patients by phenytoin. Data was collected between January 2014 and January 2020 from the neurosurgical hospital in Baghdad. Patient demographics, aetiopathology, effectiveness & side effects were recorded. Results: All the 60 patients with Post traumatic epilepsy were recorded. Regarding the Aetiology: Brain CT scan demonstrated that 35 patients had brain cortical contusions, in 15 patients there were depressed skull fractures and 10 patients had acute subdural haemorrhage. All patients with depressed skull fractures & 8 patients wit subdural haematoma were treated surgically then medically. All the patients were treated with antiepileptic medications, so that 20 patients were treated with phenytoin, 20 patients with levetiracetam & 20 patients with carbamazepine. Conclusions: Levetiracetam (Keppra) is a broad-spectrum antiepileptic drug with low incidence of cognitive problems. It is not metabolized in the liver. It has advantage over Phenytoin & Carbamazepine in management of post traumatic epilepsy due to fewer side effect
Keywords
Post-traumatic Epilepsy, Levitracetam, Phenytoen, Carbamezepine
Copyright
Copyright © Neuroquantology

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the Neuroquantology are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJECSE right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.